Business Wire

ADVA

Share
Serverius deploys ADVA FSP 3000 TeraFlex™ for 1200G transport

ADVA (FSE: ADV) today announced that Serverius, one of the Netherlands’ largest data center service suppliers, is leveraging its FSP 3000 TeraFlex™ terminal to massively increase the capacity of its deployed infrastructure. By utilizing the industry’s most comprehensive and scalable solution, Serverius is answering fierce growth in demand for its connectivity, colocation and data security services. With its ultra-flexible bandwidth modulation, TeraFlex™ enables Serverius to harness previously unused spectrum, unlocking new value in its existing fiber network. The highly compact 1RU platform optimizes all optical paths and ensures the lowest cost per bit for all fiber links. By enabling super-channels of up to 1200Gbit/s and a total capacity of 7.2Tbit/s, TeraFlex™ empowers Serverius to provide Dutch and international enterprises with a new level of capacity and throughput.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200409005014/en/

“By harnessing the very latest innovation, we’re bringing a new level of bandwidth capacity and service quality to businesses throughout the Netherlands and beyond. The ADVA FSP 3000 TeraFlex™ is key to our mission of providing world-class data center connectivity. And, with its space- and power-efficiency, it also ensures that our services remain highly affordable today and sustainable for the future,” said Sergey Petukhin, head of connectivity infrastructure, Serverius. “This deployment unlocks the full potential of our network. Now we can meet rapidly rising data demand and be sure that our infrastructure is ready to scale when our clients need even more capacity. What’s more, the openness and programmability of TeraFlex™ mean that we’re free to harness the benefits of tomorrow’s innovation without being tied to any one vendor.”

Serverius’ new solution is built on the ADVA FSP 3000 TeraFlex™, which uses software-defined fractional QAM modulation and adaptive baud rate capabilities to support 1200Gbit/s streams. By retrieving optical channel conditions via network telemetry, the platform determines the best possible capacity and spectral efficiency for each light path. This enables Serverius to exploit untapped capacity in its existing infrastructure without the cost of a complete system upgrade. Each 1RU terminal can also support up to three cards, providing easy access to capacity up to 7.2Tbit/s. What’s more, Serverius is also harnessing ADVA’s MicroMux™QSFP28 plug, which converts 100GbE client ports into ten 10GbE ports, further reducing cost, rack space and operational complexity. Cloud solution specialists Exclusive Networks also played a key role in deploying the technology.

“Serverius has a clear vision of what businesses need and a bold strategy for delivering it. By leveraging our most advanced technologies to massively increase the capacity of its fiber plant, the Netherlands’ fastest-growing cloud connectivity provider is offering its customers a vital competitive edge. With our TeraFlex™, Serverius has the power to flexibly respond to soaring data requirements and help businesses achieve their full potential,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “The strong and long-lasting relationship we have with the Serverius team was also crucial to the success of this project. By working closely with their people, we’ve been able to ensure that the new solution meets all of their particular needs while maximizing the value of their deployed infrastructure.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release

Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio

SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release

Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye